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Double stranded RNA (dsRNA), the genomic material of some viruses and a 
replication intermediate in others, is recognized by multiple signaling receptors that initiate 
the anti-viral response1.  Viruses have developed mechanisms to circumvent the anti-viral 
response by targeting components of the signaling pathway. An example of one such 
pathway is the TLR3 signaling pathway, which contains a kinase complex that activates 
interferon regulatory factor 3 (IRF3), leading to production of type I interferons.  The 
kinase complex consists of a scaffold protein, NAK-associated protein 1 (NAP1), and two 
kinases, TANK-binding kinase 1 (TBK-1) and IκB kinase epsilon (IKKε).  A fourty 
residue sequence in NAP1 was discovered that mediated its interaction with TBK1 and 
IKKε, termed the kinase binding domain (KBD)1.  However, the function of NAP1 in 
mediating kinase activation is unknown and understanding this is the long-term goal of this 
xi 
project.  The goal of this thesis was to test the dependency of NAP1’s dimeric structure on 
mediating interactions with the kinases. Biochemical characterization of recombinant 
targets was completed using size-exclusion chromatography (SEC) and NAP1 KBD WT 
eluted as a dimeric species.  CFP/YFP/Alexa Fluor 546 fusion proteins of the NAP1 KBD 
and scaffold binding motif (SBM) of the kinases, TBK-1 and IKKε, were generated to 
assess interactions using fluorescence resonance energy transfer (FRET).  NAP1 KBD 
directly interacts with TBK1 and IKKε, with low micromolar affinity in vitro.  
Mutagenesis was attempted to identify the residues necessary for NAP1 dimerization and 
any effect dimerization may have on kinase recognition.  This thesis shows data to support 
that NAP1 KBD forms stable homo-oligomers and directly interacts with a small C-
terminal portion of TBK1 and IKKε.   
1 
 
 
Chapter 1. Introduction 
 
Protein-protein interactions are responsible for a great variety of cellular functions.  
In the most basic sense, a protein-protein interaction occurs when two proteins come 
together and form some type of interaction.  Protein-protein interactions are a common 
form of communication in signaling.  For instance, when two proteins bind one another, 
activation of a different protein, post-translational modification, or recruitment of other 
proteins can occur.  This recruitment process can be performed by a class of proteins 
known as scaffold proteins, which act as docking stations for the formation of a protein 
complex, which can lead to production of type I inteferons (IFNs), Nuclear Factor-KappaB 
(NF-kB), as well as, downstream signaling to chemokines and cytokines, to destroy 
invading pathogens. 
Over the last several decades, pathogens have acquired the means to evade anti-
viral signaling2 or block receptor recognition3 as a means to promote pathogen survival and 
replication.  Viral proteins are known to interact with components of the anti-viral 
signaling response and can disable the host from sequestering the pathogen’s genomic 
material, as well as, inhibit phosphorylation-mediated signaling and block protein complex 
formation. Therefore, structurally characterizing the domains involved in these interactions 
and how they may form complexes with other proteins is vital to understanding how these 
interactions mediate cellular processes and how to counter viral evasion. 
 
2 
1.1 The Innate Immune System 
 
The immune response is comprised of two parts: innate and adaptive immunity, 
both are essential for a complete immune response.  The innate immune response is the 
first line of defense, against invading pathogens, with dendritic cells constantly sampling 
cells, both self and non-self alike, to monitor the body for an infection.  When an infected 
cell is spotted this is where the macrophages come in to do their work. Macrophages are 
known for engulfing foreign cells, via a process called phagocytosis, that are then digested 
internally and cause the release of cytokines and chemokines to transmit a local 
inflammatory response and prevent the spread of the invading pathogen to nearby cells4.  
This is one of the two main functions of the innate immune response, with the other 
function being the activation of the adaptive immune response.   
For example, the presence of a viral pathogen often leads to the production of 
interferon.  Interferons are aptly named because of their ability to “interfere” with invading 
pathogen’s replication process4.  Type-I interferons’, such as IFN-α and IFN-β, role is to 
mediate the activation of cytokines and chemokines to help prevent pathogen replication in 
infected cells.  Additionally, this activation can cause upregulation of major 
histocompatibility complex (MHC) molecules on uninfected cells5.  There are two classes 
of MHC molecules: class I and class II molecules; where class I molecules present 
peptides derived from cytosolic proteins.   Class II molecules, which are only found on a 
few specialized cell types, such as macrophages, dendritic cells and B cells, present 
peptides derived from extracellular proteins.  However, both types of molecules present 
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peptides derived from infecting pathogens for recognition by T cells, to help clear the 
infection, as part of the adaptive immune response. 
Mainly antibodies and lymphocytes carry out the adaptive immune response, which 
allows for a specific response to the invading pathogen.  However, it is the connection 
between the innate and adaptive response that is critical to fighting off the viral infection.   
 Nonetheless, the innate and adaptive immunity responses require different 
recognition sources for activation.  While the adaptive response relies on an antigen-
specific response and the innate immune response is dependent on recognition of a set of 
evolutionarily conserved pathogen elements, otherwise known as pathogen-associated 
molecular patterns (PAMPs)5.  These PAMPs form a direct interaction with a class of host 
receptors known as pattern recognition receptors (PRRs) that mediate the innate immune 
response5.  The recognition of PAMPs instead of self is what differentiates between an 
appropriate immune response and an over-active or autoimmune response, which can cause 
a variety of illnesses. 
For everything the immune response does well there are also a few drawbacks, the 
innate immune system can also lose its ability to distinguish between self and non-self, 
targeting endogenous cells as infectious agents leading to autoimmune diseases such as 
autoimmune diabetics, liver disease and lupus nephritis, a kidney autoimmune disease6.  
Furthermore, the innate immune response may also over-respond to non-infectious agents, 
creating symptoms of what are commonly referred to as allergies. While seasonal allergies 
are generally a nuisance, allergic reactions to things such as nuts or dairy can be fatal7. 
Furthermore, over the last several decades pathogens have acquired the means to evade 
4 
receptor recognition or block anti-viral signaling as a means to promote pathogen survival 
and replication (2,3). 
 
 
1.2 Pattern Recognition Receptors 
 
 The immune system response and more specifically the innate immune response 
varies depending on the evolutionarily conserved pathogen element, or PAMP, that is 
recognized.  This allows the human body to ignore self-molecules while focusing solely on 
finding, containing and destroying foreign molecules2.  The wide range of PRRs allows the 
human body to recognize an array of structural distinct bacterial and viral particles.  There 
are three localization types of PRRs: membrane-bound, cytoplasmic and secreted.  The 
membrane-bound PRRs are further classified into three subgroups: receptor kinases, which 
originated in plants, and the toll-like receptors (TLRs) and the mannose receptor, which are 
both found in humans4.   
The mannose receptors, primarily present on the surface of innate immune cells, 
recognize and bind to mannose repeats of infectious agents2.  This activation triggers 
endocytosis and phagocytosis of the invading pathogen.  As previously described, the 
engulfing of the invading particle and its subsequent digestion allows for peptide 
presentation of the foreign molecule via MHC molecules, which lead to eventual targeting 
and killing by the cytotoxic T cells.   
5 
 Recognition of both extracellular (TLR1,2,4,5,6,10) or endosomal (TLR3,7,8,9) 
PAMPs, including bacterial lipoproteins (i.e LPS) and DNA-based ligands (i.e dsRNA), is 
mediated by an array of transmembrane proteins known as TLRs.  Toll-like receptors were 
first discovered in Drosophila and are known to trigger a series of mechanisms leading to 
the synthesis and secretion of cytokines and transcription factors that are crucial to the 
development of innate and adaptative immune responses. In humans, there are currently 
eleven such receptors (TLR1-11). Interaction of TLRs with their specific PAMP induces a 
wide variety of signaling cascades consisting of NF-κB and type I interferon signaling, 
MAP kinase pathways and apoptosis and autophagy.  These pathways result in secretion of 
pro-inflammatory cytokines and chemokines, as well as, transcription factors necessary to 
activate the adaptive immune response and generate a complete immune response3.   
 
1.3 Activation of type I Interferons and NF-κB signaling 
 
One such PAMP, double stranded RNA (dsRNA), the genome of some viruses, can 
be recognized by a variety of receptors.  TLR3, retinoic acid inducible gene-1 (RIG-I), 
melanoma differentiation associated gene 5 (MDA5) and dsRNA-dependent protein kinase 
receptor (PKR) all bind dsRNA.  However, these receptor have different cellular 
localization, which leads to different downstream signaling. TLR-3 is located in the 
endosome, whereas RIG-I, MDA-5 and PKR are located in the cytoplasm6.  For example, 
when TLR3 binds dsRNA, activation can lead to three distinct signaling pathways, 
6 
resulting in production of type I Interferons or NF-kB and a third involving the cleavage of 
caspase 8, which leads to apoptosis (Figure 1).   
In the pathway leading to production of type I Interferons, the signaling cascade is 
initiated when Toll/Interleukin 1 receptor (TIR)-domain-containing adapter inducing-
interferon-β (TRIF) is recruited to TLR3’s interior-signaling domain.  TRIF via tumor 
necrosis factor receptor-associated factor 3 (TRAF3) interacts with a scaffold protein to 
mediate downstream signaling.  Currently, two scaffold proteins; Nak-associated protein 1 
(NAP1) and Similar to NAP1 TBK1 adaptor (SINTBAD) have been identified.  The 
scaffold protein(s) act as a docking site for two kinases, TRAF family member-associated 
NFKB activator (TANK)-binding kinase-1 (TBK1) and IκB kinase epsilon (IKKε).  
Together, the scaffold protein(s) and kinase(s) form a kinase complex.  The exact make-up 
of the kinase complex is not fully understood.  The activated kinases can phosphorylate 
interferon-regulatory factor 3/7 (IRF3/7) allowing these transcription factors to dimerize 
and traffic to the nucleus to initiate transcription of the interferon-β gene (IFN-β).  Upon 
transcription and release of IFN-β, it can bind to the downstream interferon alpha-receptor 
1/2 (IFNAR1/2), which triggers the JAK/STAT pathways and leads to activation of a host 
of interferon-stimulated genes.  This is the end result of the interferon response that allows 
for halting the viral replication of the invading pathogen and hopefully apoptosis of the 
viral-infected cells. 
7 
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In addition to the IRF3/7 pathway, TRIF can also initiate the nuclear factor- kappa 
B (NF-κB) essential modulator (NEMO/IKKγ) pathway, which leads to the formation of a 
kinase complex, as well.  Despite the formation of a kinase complex, like the IRF3/7 
pathway, these pathways have some distinct differences.  NEMO causes recruitment of 
two different kinases, Iκ-B kinase beta (IKKβ) and Iκ-B kinase alpha (IKKα), to form a 
kinase complex (Figure 2A). A partial crystal structure of the kinase complex8 has been 
solved; involving the minimal kinase-binding domain (KBD) of NEMO, NEMO44-111, 
which structurally is a dimer, binding two identical copies of a peptide that was generated 
from a conserved NEMO-binding domain sequence found in the two kinases, IKKα and 
IKKβ, sequence (Figure 2B). This particular conserved region is not present in the 
TBK1/IKKε kinase complex.  However, a unique conserved site, at the C-terminus, has 
been discovered in our lab via sequence alignments. 
9 
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1.4 NAP1-TBK1 mediated type I Interferon Signaling 
 
Both the NAP1 and SINTBAD scaffold proteins, also have a conserved site, that have 
been shown to recognize the kinases, TBK1 and IKKε1 (Figure 3). NAP1 has also been 
shown to bind SINTBAD; questioning whether it functions independently with the kinases 
or with the aid of another scaffold protein(s)1.  These protein-interaction domains are used 
to form large molecular weight protein interaction networks (PINs).  In fact, both NAP1 
and TBK1 were components of high molecular weight complexes in TLR3 unstimulated 
HeLa cells9.  In addition, both of these scaffold proteins have multiple predicted coiled-coil 
domains, which are rod-like alpha helices that are known to mediate protein-protein 
interactions.   
11 
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The hypothesis is that NAP1’s protein domains have interaction specificity that has a 
direct impact on its signaling (Figure 4).  This hypothesis suggests that the CC domain 
region of NAP1, residues 1-200, which highly alpha helical in structure, mediate its ability 
to homo-dimerize.  This homo-dimerization brings the kinase-binding domains in close 
proximity that they have also been shown to homo-dimerize, but more importantly is the 
hetero-interactions they form with the kinases’ scaffold-bindind motif1. NAP1’s ability to 
behave as a dimer, may be necessary for NAP1’s kinase-binding domain’s hetero-
interactions with the kinase, which is necessary for downstream signaling and production 
of type I IFNs.  The end result being to better understand the TLR3-dependent PIN and 
how it may be manipulated to control disease states. 
 
13 
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Chapter 2. Materials and Methods 
 
2.1 Bacterial Production of Recombinant Protein domains  
 
All bacterial constructs discussed below were DNA sequence confirmed and then 
transformed into BL21 Codon Plus per manufacturer’s protocol (Stratagene).  For protein 
expression, 50ml cultures were grown at 37 degrees Celsius and 200rpm in Lennox Broth 
(LB) media and ampicillin overnight and used to inoculate media for large-scale protein 
expression per manufacturer’s protocol. Cells continued to grow at 37 degrees Celsius for 
four to six hours (2.1.2) or at 20 degrees Celsius overnight (2.1.1 and 2.1.3), before 
harvesting. Cells were harvested by centrifugation, 8000 rpm for 20 minutes, and cell 
pellets were stored at -80°C. 
 
2.1.1 CFP/YFP Tagged Protein Purification 
 
All constructs used for FRET assays were made prior to starting on this project (CFP 
NAP1 KBD, CFP, YFP, YFP TBK1 SBM, GST TBK1 SBM and GST IKKε SBM).  
However, all CFP and YFP fluorescent-tagged constructs were found to be dimeric.  
Quikchange mutagenesis kits (Stratagene) that employed standard molecular biology and 
polymerase chain reaction (PCR) techniques were used to generate monomeric fluorescent-
tagged (A206K) constructs as per manufacturer’s protocol.  An additional mutation was 
performed to change YFP constructs to Citrine variants (Q69M).  Constructs made include: 
15 
mCFP NAP1 KBD, mCFP, mCitrine TBK1 SBM, mCitrine.   All CFP/YFP constructs are 
in pET15b, a bacterial expression vector that includes an N-terminal 6xHistidine tag for 
immobilized metal affinity chromatography purification following expression. Additional 
mutants were made to the mCFP NAP1 KBD to test their effects on dimer stability.   
For purification, cell pellets were resuspended in Binding Buffer (20mM PO4 (pH 8), 
500mM NaCl, 2mM MgCl2 and 1mM beta-mercaptoethanol (βME) including 1 protease 
inhibitor tablet) and purified per manufacturer’s protocol (Qiagen).  Cell lysis was 
performed, on ice, using a Avestin C3 emulsifier instrument.  Passage was performed 3-4 
times at 15K-20K psi.  Run program “1ml Histrap cfp proteins RJC” while collecting 1ml 
fractions using the AKTA system at 4 degrees Celsius.  This program washes the column 
with 20 CV of 100% Binding Buffer, 10 CV gradient from 0 to 10% Elution Buffer, 
washes with 5 CV of 10% Elution Buffer, 25 CV gradient from 10 to 100% Elution Buffer 
and washes with 10 CV of 100% Elution Buffer.  Peak fractions are analyzed by SDS-
PAGE gel analysis for target protein and visualized with coomassie blue stain.  Histrap 
column is regenerated per manufacturer’s instructions (Qiagen). 
 
2.1.2 Purification and Refolding of Recombinant Protein  
 
NAP1CC, the first 200 amino acids, was expressed as insoluble material.  To purify 
the insoluble NAP1CC, the insoluble protein was extracted from the bacterial pellet using 
6M GuHCl.  Purification by nickel-nitrilotriacetic acid (Ni-NTA) resin was completed 
16 
following the manufacturer’s instructions for batch purification under denaturing 
conditions (Qiagen).  
 
2.1.3 Glutathione-S-Transferase fusion tagged construct purification 
 
 The GST fusion proteins are in the pGEX-4T1 vector, a bacterial expression vector 
that includes a Glutathione-S-transferase tag for affinity chromatography purification 
following expression, per manufacturer’s protocol (GE Healthcare). Quikchange 
mutagenesis kits (Stratagene) that employed standard molecular biology and polymerase 
chain reaction (PCR) techniques were used to mutate a valine to a cystine residue at the N-
terminus of the TBK1 SBM peptide to allow for linkage with the Alexa-Fluor 546 
molecule.  
 
2.2 Baculovirus Production of Recombinant kinases 
2.2.1 pFastbac Construct Preparation 
 
Dr. Katherine Fitzgerald (UMass-Amherst) kindly provided a pFASTBAC vector 
containing an N-terminal FLAG-affinity tag followed by the TBK1 gene.  The IKKε gene 
was later cloned into the same expression vector using primers that contained unique 
restriction sites (5’ BamHI and 3’ SpeI) for the pFASTBac vector multiple cloning site.   
 
17 
2.2.2 Bacmid Generation  
 
Sequence confirmed IKKε pFASTBac and TBK-1 pFASTBac DNA was 
transformed into DH10Bac competent cells per manufacturer’s protocol (Invitrogen).  
 
2.2.3 Bacmid DNA Purification  
 
Overnight cultures of pFASTBac transfected DH10Bac cells were pelleted at 
14.000 x g for 10 minutes at room temperature.  DNA was extracted via Qiagen mini-prep 
kit, but modified to the Bac-to-Baculovirus Invitrogen protocol.  
 
2.2.4 Insect Cell Virus Propagation  
 
All insect cell work was carried out using sterile technique in a laminar flow hood, 
biosafety cabinet IIA.  Sf-9 cells were cultured in Hyclone SF-X Media (Thermo 
Scientific).  For bacmid transfection, again Bac-to-baculovirus protocol was followed 
(Invitrogen).   
 
2.2.5 Determining Viral Titer  
 
Viral titer plaquing assays to determine viral titer were completed as per Bac-to-Bac 
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instruction manual (Invitrogen).  Sf-9 cells were plated at a density of 1.0 x 106 cells/well in 
two 6-well culture plates. Cells were allowed to adhere at room temperature for 1 hour.  
Meanwhile, serial dilutions of P2 viral stock were made from 10-1 to 10-8 fold dilutions in 
SF-X media.  Cell adherence is confirmed before removal of media.  Media is then removed 
from wells and replaced with 1 ml of diluted virus (from 10-3 to 10-8 ). Each dilution of 
virus was done in duplicate, along with a control (no viral addition).  Wells were allowed to 
incubate with virus for 1 hour at room temperature on an orbital shaker, slow speed.  Low 
melting temperature agarose (4 %, 10 ml) and 30 ml of SF-X media were warmed to 37°C, 
and then combined to make plaquing media.  After incubation, plates were returned to 
hood, and plaquing media was allowed to cool but not thicken to prevent cell death.  Viral 
dilution media was removed from cells, and 2ml of plaquing media (cooled slightly) was 
added to wells, slow addition along the wall of the well.  Plaquing media was allowed to set 
for 10-20 minutes with the lid slightly cracked to avoid condensation. Plates were placed in 
a virus-specific incubator at 27°C for 4 days.  After four days, 1 ml neutral red staining 
solution, consisting of 1% agarose, 62.5 µg/ml neutral red stain in SFX media, was added to 
each well to stain the plaques. Agarose was allowed to harden and plates were returned to 
humidified incubator for 2-3 days. Plaques (cleared areas) were counted for each well, and 
averaged for each dilution. Titer was calculated by: 
 
Titer (pfu/ml) = (# of plaques) x (dilution factor) x (1ml of inoculum/well) 
 
Viral stocks were replenished using the protocol described for P2 viral stock and titred as 
19 
described above. 
 
2.2.6 Baculovirus Expression and Protein Purification 
 
Sf9 cells cultured in suspension were infected with FLAG-tagged TBK1 or IKKε 
incorporated baculovirus as described in the literature10 to express the kinases.  The cells 
were infected at a cell density of 1.5 x 106 cells/ml with a multiplicity of infection (MOI) 
of three.  Cells were harvested fourty-eight hours post-infection and then lysed by 
emulsification (Avestin Emulsiflex C3) at 20,000 psi.  The kinases were purified from 
clarified cell lysates by anit-FLAG M2-agarose affinity column chromatography as per 
manufacturer’s protocol (Sigma) and eluted using 0.34mg/ml of FLAG peptide.  SEC was 
performed to remove the FLAG peptide from the kinase solution.  Fractions containing 
kinase were concentrated, where the concentration was determined by Biorad assay with a 
1000-fold dilution of protein to Biorad reagent.  Kinase was stored at -80 degrees Celsius 
in kinase storage buffer: 20mM Tris-HCl (pH 7.6), 150mM NaCl, 0.1% Nonidet P-40, 
10% glycerol, 20mM NaF, 20mM β-glycerophosphate, 1mM EDTA, 5mM DTT, 1 EDTA-
free protease inhibitor tablet, 0.1%BSA as detailed10. 
 
2.3  mCFP NAP1 KBD Protein Interactions 
2.3.1 Molecular Modeling 
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The Protein Databank (PDB) was used to find a related structure of a coiled-coil 
domain protein.  The crystal structure of the C-terminal region of striated muscle alpha-
tropomyosin (1KQL) was used as a template and all the residues were mutated to match 
the target sequence (NAP1 216-255) using Pymol.  Once mutated the structure was energy 
minimized using a program called PHIEX.  Following minimization, two copies of the 
structure were sent for analysis for docking interactions, using a program called ZDOCK, 
which holds one structure fixed and rotates the other structure to it and outputs possible 
interactions arrangements for the pair.  Possible complexes are scored and ranked based on 
shape complementarity, desolvation, electrostatics and free energy change.  
2.3.2 Size Exclusion Chromatography  
 
Elutions from Ni-NTA purification and FLAG purification were separated on a 
Superdex™ 200 16/60 prep grade column (GE Healthcare) pre-equilibrated in 20 mM 
HEPES, pH 7.5, 150 mM NaCl and 1 mM βME (Ni-NTA purifications) and 20 mM 
HEPES, pH 7.5, 500 mM NaCl, 5% glycerol and 1 mM DTT (FLAG purifications), 
respectively.  Elution volumes at peak maximums were converted to Kav and compared to a 
standard curve (Kav versus log molecular weight) based upon globular standards of known 
molecular weights (previously derived) using this equation: 
Kav =   elution volume – void volume 
total volume – void volume 
 
Peak fractions for all runs were analyzed by 10% SDS-PAGE and visualized with 
coomassie blue stain. 
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2.3.3 Fluorescence Resonance Energy Transfer 
 
 
 The kinase-binding domain (KBD) of NAP1 was linked to cyan fluorescent protein 
(CFP) and the kinase’s interaction motif was fused to citrine fluorescent protein (CitFP). 
Fluorescence resonance energy transfer (FRET) between CFP and CitFP was measured to 
assess interactions, by exciting at 430nm and following emission at 530nm.  Alternatively, 
the kinase’s interaction motif was conjugated to the fluorophore Alexa Fluor 546 (AF546).  
Again, examining the interactions, by exciting at 430nm and following emission at 570nm. 
Fluorescence measurements were performed using a Fluorescence Spectrophotometer 
(instrument name). The excitation and emission bandpass were both set at a value of 2nm.  
Emission spectra were collected from a range of 450nm to 600nm with data points being 
collected every nm and each spectrum was collected three times and averaged.  
 
 
 
 
2.4 Purification and Isolation of IKKε  SBM-546 labeling 
 
Upon successful purification of the GST IKKε SBM protein it was coupled with 
mCFP NAP1 KBD were examined for hetero-interactions via fluorescent resonance energy 
transfer (FRET).  Prior to completing the FRET experiments, IKKε SBM was cleaved, 
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using 10U thrombin/mg target protein, to separate the peptide from the GST-tag.  Upon 
successful cleavage of the fusion protein, free GST-tag is allowed to bind to Glutathoine-
S-transferase 4B resin and thrombin is allowed to bind benzamidine resin, thus, leaving 
only the IKKε peptide in the supernatant.  Upon isolation of the IKKε peptide, verification 
analysis using mass spectrometry (MS) was performed by Jimmy Marion (of the Bell lab).  
After confirmation of successful peptide isolation the peptide is labeled using a small 
molecule fluorophore, Alexa-Fluor 546, per manufacturer’s protocol (Invitrogen).  This 
process is verified using MS that was performed by Jimmy Marion (of the Bell lab).   
 
2.5 Protein Concentration  
 
Protein concentrations were determined by BioRad protein assay (BioRad) as per 
manufacturer’s protocol. As needed, protein samples were concentrated by ultrafiltration 
(Amicon Ultrafiltration Units). 
 
2.6 Circular Dichroism and Thermal Melt  
 
NAP1CC sample were dialyzed into 100 mM sodium phosphate, pH 7, 150mM 
NaCl, 5% glycerol overnight at 4°C. Dialysis buffer was retained as a buffer blank.  CD 
spectra (190-300nm) were collected on a Jasco 720 Circular Dichroism Spectrometer via 
collaboration with Dr. Ellis Bell at the University of Richmond.  Five individual spectra 
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collecting data points every 0.1nm were collected averaged and Savitz-Golay smoothed 
using the Jasco Spectra Manager software.  
Thermal melt data were collected from 4°C-90°C at A222nm.  Data was collected at 1 
degree Celsius intervals.  Data were Savitz-Golay smoothed using the Jasco Spectra 
Manager software. 
 
2.7 Analytical Ultracentrifugation (work done by R. Ghirlando) 
 
Sedimentation velocity experiments were completed by R. Ghirlando (NIH).  Data 
was collected at 4 degrees Celsius, 55K rpm and various protein concentrations (33-
134µM) 0.435 to 3.49mg/ml in 20mM HEPES (pH 7.5), 150mM NaCl and 1mM βME. 
Dialysis buffer was retained as a buffer blank.  Protein concentrations were determined by 
Biorad assay (2.4).  Data was analyzed in terms of a continuous c(s) sedimenting species, 
which provides a concentration profile (c) for each sedimenting species with a 
sedimentation coefficient s.  Data was fitted using SEDFIT program.  Plots were completed 
showing the concentration (in terms of A280) as a function of best fit (s20w).
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Chapter 3.  Results 
 
 
Toll-like receptor 3 (TLR3) is stimulated by dsRNA, the viral genomic material in 
some viruses or a viral replication intermediate in others.  This stimulation initiates 
signaling cascades that lead to the activation of nuclear factor kappa B (NF-κB) and 
IRF3/7.  Within the TLR3 signaling cascade that activates interferon regulatory factor 3/7 
(IRF3/7), two scaffold proteins, Nak-associated protein 1 (NAP1) and Similar to NAP1- 
TBK1 adaptor (SINTBAD), can recruit and bind two kinases, TRAF family member-
associated NFKB activator (TANK)-binding kinase 1 (TBK1) and IkB kinase epsilon 
(IKKε), which phosphorylate IRF3/7 and promote production of type I interferons (IFNs), 
NF-kB, as well as, downstream signaling to chemokines and cytokines, to destroy invading 
pathogens. 
 
3.1 Nak-associated protein 1 (NAP1) interactions via coiled-coil (CC) domain 
3.1.1 Expression and Purification 
 
Full-length NAP1 was expressed as insoluble material via bacterial expression. So, 
quikchange mutagenesis was performed to truncate the NAP1 full-length protein to contain 
only its first 200 amino acids, NAP1CC (residues 1-200) (Figure 5).  This construct was 
generated in pET15b, a bacterial expression vector that includes an N-terminal 6xHistidine 
tag for immobilized metal affinity chromatography purification following expression.  
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However, NAP1CC was also expressed as insoluble material.  To purify the insoluble 
NAP1CC, the bacterial pellet was resuspended and the protein unfolded using 6M-
guanidine hydrochloride (GuHCl).  Purification by nickel-nitrilotriacetic acid (Ni-NTA) 
resin was completed following the manufacturer’s instructions for batch purification under 
denaturing conditions (Qiagen). NAP1CC was eluted in 5ml aliquots with 0.5M imidazole 
in binding buffer.  Purity was assessed by separation by SDS-PAGE and coomassie stain 
(Figure NAP1CC purification) 
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3.1.2 Circular Dichroism and Thermal Melt 
 
Successful refolding was assessed by examining secondary structure content using 
circular dichroism (CD).  A UV-Vis scan was collected, via CD, and can detect secondary 
structures motifs, such as alpha helices and beta sheets.  NAP1CC, which encompasses 
only the CC region, should contain almost exclusively alpha helical secondary structure.  
The CD spectrum of NAP1CC shows two negative ellipticity peaks at 222 and 208nm 
(Figure 6A), which is indicative of alpha helical secondary structure.  Furthermore, the 
thermal melt data (Figure 6B) indicates a stepwise loss of helical content as the 
temperature is increased.  This suggests that NAP1CC forms higher order oligomers and 
that as the temperature is increased the monomers dissociate and eventually the individual 
alpha helices are separated, as well.   
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3.1.3 Size-exclusion chromatography (SEC) 
 
To access the oligomeric state of the NAP1CC protein (Figure 7A), SEC experiments 
were completed.  SEC separates proteins in the liquid phase as a function of their ability to 
interact with a column matrix.  Larger proteins elute first because of their inability to 
interact with the matrix while smaller proteins elute later.  An approximate molecular 
weight of an eluted species can be determined based upon the elution pattern of globular 
protein with well-characterized molecular weights.  NAP1CC was tested at three different 
concentrations: 0.1mg/ml, 1.2mg/ml and 20mg/ml (Figure 7B).  All of the experiments 
were completed on a Superdex 200 column (GE) in the following buffer: 20 mM HEPES 
(pH 7.5), 150mM NaCl, 5% glycerol and 1mM DTT.   
The elution profile of NAP1CC indicated the major species eluted as a hexamer (Figure 
?) with a minor peak eluting as a 12-mer. CC domains are rod-like structures, which 
tumble in solution with a larger radius than a globular protein with similar molecular 
weight.  Therefore, while SEC is useful in determining purity of these types of protein 
samples, it may only approximate the molecular weight.   
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3.1.4 Analytical Ultracentrifugation (AUC) (completed by Dr. R. Ghirlando) 
 
As a complementary technique AUC was utilized to obtain a more accurate molecular 
weight.  The data collected via AUC includes sedimentation and diffusion coefficients that 
contain information concerning the size and shape of a protein.  A buoyancy term is also 
derived, which can account for the tumbling limitations of SEC.  Using all these pieces of 
data, a more accurate molecular weight can be calculated.  In collaboration with Dr. 
Rodolfo Ghirlando (NIDDK, NIH), AUC sedimentation velocity studies were performed 
on the “hexamer” species to confirm the data collected by SEC (Figure 7).  Concentrations 
ranging from 17 to 137mM (0.435 to 3.49mg/ml) were tested to determine oligomeric state 
and examine concentration dependence of association (Figure 8).  AUC analysis of this 
protein indicates that NAP1CC actually behaves as a dimer in vitro.  This validated the 
need to include both SEC and AUC to determine accurate homointeractions of these 
coiled-coil domain proteins. 
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NAP1 (1-200)
Sedimentation Coeff. (S)
Figure 8. NAP1CC is a dimeric species by AUC. Analytical ultracentrifugation data, sedimentation coefficient (S) profiles, of
NAP1CC were collected for samples from a concentration range of 17.2 to 137 µM in 0.02 M HEPES, pH 7.5, 0.5 M NaCl, 5%
glycerol, 1 mM βME.  Samples were run at 55 K rpm and 20°C.  The major peak having an S value of 2.67 corresponds to a
molecular weight of ~44 kDa just slightly less than a NAP1CC dimer (~51 kDa).
AUC data were collected by Dr. R. Ghirlando at NIDDK, NIH, Bethesda, MD.
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3.2 Attempts to obtain full-length TBK1 and IKKε  via Baculovirus system 
3.2.1 Generation of TBK1/IKKε  full-length Baculovirus 
 
Dr. Katherine Fitzgerald kindly provided the pFASTBAC vector containing an N-
terminal FLAG-tagged TBK1 gene (Figure 9A).  This vector backbone was used to 
construct an equivalent expression vector with the IKKε gene using standard molecular 
biology techniques (Stratagene).  Both TBK1 and IKKε pFASTBAC constructs were then 
DNA sequence confirmed.  Bacmid DNA was generated using Invitrogen’s Bac-to-Bac® 
Baculovirus protocol (Figure 9B-C). Virus was amplified in additional cultures to yield 
500ml of viable virus per construct at a titer between 1x108 plaque forming units/milliliter 
(pfU/ml) and 1x109 pfU/ml.   
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3.2.2 Expresssion and Purification of TBK1/IKKε  FLAG-tagged proteins 
 
Sf9 cells cultured in suspension were infected with TBK1 or IKKε incorporated 
baculovirus as described in the literature (14) to express the kinases.  The cells were 
infected at a cell density of 1.5-2 x 106 cells/ml with a multiplicity of infection (MOI) of 
three.  Cells were harvested fourty-eight hours post-infection and then lysed by 
emulsification (Avestin Emulsiflex C3) at 20,000 psi.  The kinases were purified from 
clarified cell lysates using anit-FLAG M2-agarose affinity column chromatography as per 
manufacturer’s protocol (Sigma) and eluted using 0.34mg/ml FLAG peptide in two 
twenty-five milliliter fractions and concentrated by ultra-filtration (Amicon Ultra- 3000 
molecular-weight cut-off (MWCO).  To remove FLAG peptide from elution fractions it 
was purified by separation on a Superdex 200 column (Figure 10) and checked for purity 
by separation by SDS-PAGE, coomassie stain (Figure 11A).  Fractions containing kinase 
were concentrated and protein concentration was determined by Biorad assay.  Kinases 
were stored at -80 degrees Celsius in kinase storage buffer: 20mM Tris-HCl (pH 7.6), 
150mM NaCl, 0.1% Nonidet P-40, 10% glycerol, 20mM NaF, 20mM β-glycerophosphate, 
1mM EDTA, 5mM DTT, 1 EDTA-free protease inhibitor tablet, 0.1%BSA as detailed 
(14). Low protein yields, limited the use of recombinant kinase proteins in future assays. 
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3.3 Nak-associated protein 1 (NAP1) interactions via kinase-binding domain (KBD) 
interactions 
3.3.1 Generation of CFP/YFP-tagged constructs 
 
Thus, in order to examine the potential interactions between TBK1/IKKε and the 
scaffold protein, NAP1, a smaller domain of the kinases, as well as, for the scaffold 
protein, were generated.  Previous work completed in the lab lead to generation of cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) fusion proteins containing 
NAP1 kinase-binding domain (KBD) and TBK1 scaffold-binding motif (SBM) peptides.  
For example, NAP1 KBD (residues 216-255), the target gene, was inserted into the 
pET15b vector that included a N-terminal 6X His-tag followed downstream by a CFP 
molecule and then the target gene (Figure 12A), in this case NAP1 KBD (residues 216-
255).  A similar construct was generated using YFP that was fused with the SBM of TBK1 
(residues 700-722), for Fluorescence-resonance energy transfer (FRET) pairing 
experiments with NAP1 KBD. CFP and Citrine proteins, containing no peptides, were also 
generated to serve as controls for the FRET experiments.  
However, purification of these constructs showed that they all expressed as dimeric 
species.  It was determined that a key mutation needed to be made to force the 
fluorophores to behave monomeric. Quikchange mutagenesis kits (Stratagene) that 
employed standard molecular biology and polymerase chain reaction (PCR) techniques 
were used, as per manufacturer’s protocol, to mutate residues to make the fluorescent 
proteins monomeric (A206K).  Furthermore, a mutation was introduced to change YFP to 
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Citrine (Q69M), an YFP variant, because of its emission range overlap with CFP excitation 
range, which is a requirement for good FRET pairing.  
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pET15b
A
Figure 12. NAP1 KBD is a dimeric species by SEC.  A) Cartoon diagram of monomeric cyan fluorescent protein (mCFP) NAP1
KBD plasmid. B) Cartoon diagram of glutathione-S-transferase (GST) tagged kinase SBM plasmid.  All constructs were generated
for use in fluorescence resonance energy transfer studies.
B
pGEX-4T™1
ATG-6XHis-NdeI-FP-XhoI-insert-TAA-BamHI
ATG-GSTtag-BamHI-insert-TAA-XhoI
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3.3.2 Generation of GST-TBK1/IKKε  SBM for labeling with Alexa-Fluor 546  
 
Both TBK1 and IKKε (687-709) SBMs were inserted into the pGEX-4T1 vector 
(Figure 12B), a bacterial expression vector that includes an N-terminal Glutathione-S-
transferase tag for affinity chromatography purification following expression. Quikchange 
mutagenesis kits (Stratagene) that employed standard molecular biology and polymerase 
chain reaction (PCR) techniques were used, as per manufacturer’s protocol, to insert a 
cysteine residue at the N-terminal of the TBK1 SBM peptide that allows for linkage with 
an Alexa-Fluor 546 molecule and use in small-molecule FRET experiments.   
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3.3.3 Expression and Purification 
 
The pET15b constructs are purified from cell lysates by binding to a Ni2+ charge 
immobilized metal affinity chromatography (IMAC) resin, HISTRAP, washed with 
binding buffer (20 mM NaPO4 (pH 8), 0.5M NaCl, 1mM βME) and eluted using a gradient 
of imidizaole (0 – 0.5M) in binding buffer as modified per manufacturer’s instructions (GE 
Healthcare).  Fractions containing target protein, as assessed by separation on SDS-PAGE 
and coomassie staining, were pooled, concentrated and further purified by separation on a 
Superdex 200 column (Figure 13-14) and checked for purity by separation by SDS-PAGE, 
coomassie staining (Figure 15A-B, 16A-B).   
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The GST fusion proteins, using the pGEX-4T1 vector, were expressed in bacteria as a 
soluble protein and purified from clarified cell lysates using standard protocol provided by 
the manufacturer (GE Healthcare) for Glutathione Sepharose 4B resin and assessed for 
purity by separation by SDS-PAGE and coomassie stain (Figure 11B).  Following 
successful purification of the GST IKKε SBM protein, the GST-tag was cleaved with 
thrombin (10units/mg of target protein) per manufacturer’s protocol (GE Healthcare) and 
confirmed via mass spectrometry (Figure 17A).  Pure peptide was assessed for secondary 
structure formation via CD spectrum (Figure 17B) and appears to have mainly alpha 
helical content. 
 
3.3.4 NAP1 KBD homo-interactions analyzed via SEC 
 
The kinase binding domain (KBD) of NAP1 was also examined for homo-
interactions using SEC.  During initial purification experiments it eluted as a dimer, while 
the other CFP/Citrine-tagged proteins eluted as a monomer (Figure 13-14).  To determine 
if the dimer is concentration dependent, mCFP NAP1 KBD was run over a S200 tricorn 
column (GE) in the following buffer: 20 mM HEPES (pH 7.5), 150mM NaCl, and 1mM 
βME.  mCFP NAP1 KBD was analyzed over the concentration range 1 to 6mg/ml (Figure 
18).  The results showed that, at concentrations below 2mg/ml, mCFP NAP1 KBD eluted 
as a monomer, while at concentrations above this threshold it eluted as a dimeric species.  
Furthermore, when mCFP, with no peptide fused, was analyzed at the 6mg/ml 
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concentration it eluted as a monomeric species.  Thus, the NAP1 KBD is mediating the 
dimer formation and not the CFP molecule. 
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3.3.5 NAP1 KBD homo-interactions assessed via a molecular model 
 
It has been shown that the first 200 residues of the NAP1 protein (Figure 8) and the 
NAP1 KBD (Figure 18) are dimeric in structure. Other data collected in the lab (data not 
shown) has successfully expressed and purified GST-tagged NAP1 KBD (performed by 
James Marion).  CD was completed to assess the secondary structure of this region of 
NAP1, which was determined to be almost exclusively alpha helical (data not shown). 
Therefore, when the two adjacent domains were combined in either the head-to-head or 
head-to-tail orientation, it becomes clear that, in order for both domains to have homo-
interactions, the NAP1 protein must be in a head-to-head confirmation (Figure 19). 
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To identify the essential residues for maintaining the homo-dimer of NAP1 KBD a 
molecular model was built; following the diagram in Figure 20.  A single chain from the 
striated muscle alpha-tropomyosin (1KQL) was used as template; its amino acids were 
mutated to the NAP1 KBD (216-255) sequence using Pymol and energy minimized via 
Phenix (Figure 21A).  Identical copies of the NAP1 KBD sequence were input into 
ZDOCK.  Keeping one molecule stationary, the other was computationally docked to the 
stationary molecule.  
The program scored complexes based upon shape complementarity, desolvation, 
electrostatics and free energy change.  Additionally, based on analysis of previously 
collected data, (Figure 19) head-to-head complexes in the top ten scored were examined. 
Of the ten highest scores, only two were in the head-to-head confirmation.  The two 
highest scoring models that met this criteria are shown in, Figure 21B-C.  Both were 
analyzed, using Pymol, for residues that would form strong interactions at the interface of 
the hydrophobic core, as well as, possible electrostatic interactions; hallmarks of coiled-
coil domain structures, such as NAP1 KBD.   
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Figure 21.  Molecular model of NAP1 KBD and dimer interface.  A) NAP1 KBD model (residues 216-255) was built using
striated muscle alpha-tropomyosin and the GCN4 leucine zipper fusion structure (1KQL3) as template and then energy minimized
(Phenix4).  B) Computational docking (ZDOCK5) was used to predict dimer interface of NAP1 KBD.  From previous data, the
dimer must form a head-to-head interaction.  The two highest scoring models that met this criteria are shown.
A B
NAP1 KBD
model
NAP1 KBD
Dimer model A
NAP1 KBD
Dimer model B
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3.4 Kinase-binding domain and Kinase Interactions 
3.4.1 NAP1 KBD-TBK1 SBM Interactions 
 
Successful purification of mCFP NAP1 KBD and mCitrine TBK1 SBM proteins 
allowed for assessment of hetero-interactions, as well as, any kinase protein affinity to 
NAP1, via FRET based assays. 
Fluorescent properties of donor and acceptor 
 Fluorescence resonance energy transfer (FRET) is based on a couple properties.  In 
order to achieve FRET a couple properties must be met.  First, the FRET pair, donor and 
acceptor, must be in close contact, approximately 10-100 Angstroms.  The FRET pair must 
be in close contact to allow for energy transfer from the donor to the acceptor.  In order to 
achieve such a phenomenon, known as the spectral overlap, the emission spectrum of the 
donor must overlap with the excitation spectrum of the acceptor.  To determine where this 
occurs for this particular FRET pair, the donor, mCFP NAP1 KBD or mCFP, was emitted 
at 475nm and an excitation scan (from 300-450nm) and an emission scan (from 450-
650nm), exciting at 430nm, were collected separately for both mCFP NAP1 KBD and 
mCFP (Figure 22).  The acceptor, mCitrine TBK1 SBM or mCitrine, was emitted @ 
530nm and an excitation scan (from 300-525nm), and an emission scan (525-650nm), 
exciting at @475nm, were collected (Figure 23), as well.  
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FRET experimental set-up 
Based on these spectra, the donor, mCFP NAP1 KBD, was excited at 430nm and 
emission spectra were collected (from 450nm to 600nm) to observe the interaction between 
mCFP NAP1 KBD and mCitrine TBK1 SBM (Figure 24), to obtain optimal experimental 
results.  A total of four scans were completed every 1nm for each concentration of the 
acceptor.  The concentration of the donor, mCFP NAP1 KBD, was held constant at 0.5µM, 
a concentration low enough not to force dimerization of the mCFP molecule, and aliquot 
into a set of cuvettes.  While the acceptor, mCitrine TBK1 SBM was added to these 
cuvettes separately at concentrations ranging from 0-6 µM, large enough to observe FRET 
pairing.  FRET buffer (20mM HEPES pH 7.5, 150mM NaCl, 1mM βME) was added to 
maintain constant volume in all cuvettes.  
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While the majority of the energy transfer from donor to acceptor is from the two 
peptides interacting, it is possible to get non-specific interactions between the two 
fluorphores, mCFP and mCitrine.  To correct for this, the interaction between mCFP NAP1 
KBD and mCitrine (Figure 25) was observed by excitation of the donor, mCFP NAP1 
KBD, at 430nm and emission spectra were colleted (from 450nm to 600nm) to measure the 
non-specific interaction.  The experimental set-up was the same as described above. 
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Data Analysis 
Upon completion of the spectra, a correction factor is calculated, to adjust for 
difference in fluorescence intensity between the mCFP and mCitrine fluorphores.  This 
correction factor is the fluorescence intensity between mCitrine:mCitrine TBK1 SBM at 
530nm, the excitation maximum for mCitrine: 
 
Fluorescence Intensity @ 530nm of mCitFP                  
 Fluorescence Intensity @ 530nm of mCitFP TBK1 SBM  
 
 With this correction factor, (value of 1.4) any difference in fluorescence intensity between 
the mCFP and mCitrine fluorophores: 
 
(experimental FI @530nm)- (( control FI @530nm)/1.4) 
 
After this correction is applied the net fluorescence (Figure 26A) was fit to a binding curve 
(FI @ 530 vs. log [mCitFP TBK1 SBM (nM)] where the KD is approximately 2µM (Figure 
26B). 
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3.4.2 NAP1 KBD-IKKε  SBM Interactions 
 
Alexa-Fluor 546-Labeling of IKKε SBM peptide 
Successful purification of pure IKKε SBM was labeled with Alexa-Fluor 546 per 
manufacturer’s protocol (Invitrogen) and following the diagram in Figure 27.  No mutation 
was made, because a cysteine residue was already present at the N-terminus. Labeling 
occurs through disulfide-linkage between the thiol groups of the cysteine residue and the 
C5-malamide of the Alexa-Fluor.  
Alexa-Fluor 546 (AF546), 1mg, is dissolved in 333µl of FRET buffer, for a final 
concentration of .33µM.  AF546 is added at the 3X the concentration of the target peptide 
to label.  FRET buffer is added for necessary dilutions.  The reaction is allowed to go for 2 
weeks at 4° Celsius and excess label is remove via a desalting column, 3x 3’ spins 
@1500rpm.  Successful labeling of peptide was assessed again via mass spectrometry 
(Figure 17C), for use in small-molecule FRET experiments.  
Fluorescent properties of donor and acceptor 
 To determine where the spectral overlap occurs for this particular FRET pair, the 
acceptor, AF546 IKKε-SBM, was emit at 570nm and an excitation scan (from 300-565nm) 
and an emission scan (from 550-650nm), exciting at 520nm, were collected separately 
(Figure 28).  The donor, mCFP NAP1 KBD, has already been characterized (Figure 22). 
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FRET experimental set-up (Ellis Bell) 
Based on these spectra, the donor, mCFP NAP1 KBD, was excited at 430nm and 
emission spectra were collected (from 450nm to 650nm) to observe the interaction between 
mCFP NAP1 KBD and AF546 IKKε SBM (data not shown), to obtain optimal 
experimental results.  A total of four scans were completed every 1nm for each 
concentration of the acceptor.  A set amount of the acceptor, AF546 IKKε, at unknown 
concentration, was added to a cuvette and the donor, mCFP NAP1 KBD, was held titrated 
in, at concentrations ranging from 0-3 µM, large enough to observe FRET pairing.  FRET 
buffer (20mM HEPES pH 7.5, 150mM NaCl, 1mM βME) was added to maintain constant 
volume in all cuvettes.  Scans were performed after the addition of each aliquot of mCFP 
NAP1 KBD. 
Again, non-specific interactions between the two fluorphores, mCFP and AF546 
were corrected for.  For this set-up, the same experiment was performed as for the 
experimental, however, no AF546 IKKε SBM was added and only buffer was in the 
cuvette to start and again mCFP NAP1 KBD was titrated in.   
Data Analysis 
This data was corrected by subtraction of the integrated area of the resonance 
energy transfer (RET) signal for the control spectra from the experimental spectra.  The 
raw data was fit to a binding curve (integrated area of the RET signal vs. mCFP NAP1 
KBD (µM)) where the KD is approximately 1µM (Figure 29).  This agrees with the NAP1 
KBD-TBK1 SBM data, indicating that mCFP NAP1 KBD interacts with both the kinase’s 
SBMs at low-micromolar affinity. 
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Chapter 4. Discussion 
 
The data shows that NAP1 protein domains form head-to-head dimers.  Furthermore, 
homo-dimerization of the NAP1CC region may mediate homo-dimer formation of the 
NAP1 KBD, but more importantly is the hetero-interactions they form with the kinases’ 
SBM.  The CC domain region, as well as, NAP1’s ability to behave as a dimer, may 
mediate NAP1 KBD’s hetero-interactions with the kinase.  This interaction has been 
shown to be necessary for IRF3 phosphorylation leading to production of type I IFNs.   
 It has previously been reported that the type I IFN pathway has a second scaffold 
protein, SINTBAD.  Both the NAP1 and SINTBAD scaffold proteins, have a conserved 
site, specific for kinase, TBK1 and IKKε1, recognition. NAP1 has also been shown to bind 
SINTBAD; questioning whether it functions independently with the kinases or with the aid 
of another scaffold protein(s)1.  These protein-interaction domains are used to form large 
molecular weight protein interaction networks (PINs).  In fact, both NAP1 and TBK1 were 
shown to be associated with high molecular weight complexes in TLR3 unstimulated HeLa 
cells9.  In addition, both of these scaffold proteins have multiple predicted coiled-coil 
domains, which are rod-like alpha helices that are known to mediate protein-protein 
interactions.  However, the mechanism behind the NAP1-TBK1 interaction, which is 
required for IRF3 phosphorylation leading to production of type I IFNs, is unknown.  
While all the FRET data was collected with mCFP NAP1 KBD in its monomeric state, it 
has not been determined if mCFP NAP1 KBD at dimeric concentrations would tighten 
hetero-interactions with the kinases.  This work is currently ongoing. 
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As previously mentioned, the Randow group has identified some key residues that 
have diminished the scaffold-kinase binding, which are colored orange in the helical wheel 
representation (Figure 30). These residues are found on the dimer interface and necessary 
for stabilizing the hydrophobic core.  Conversely, mutation sites that had no effect on 
kinase binding, because they lie outside the dimer interface, are colored purple (Figure 30).  
Therefore, it is possible that dimer formation may enhance and stabilize hetero-interactions 
with the kinases.  Furthermore, polar amino acids have been shown to contribute to 
specificity of hetero-dimer formation by favoring associations with complementary polar 
groups.  For example, Tyr-223 of the NAP1 KBD when mutated to Ala shows complete 
loss of NAP1-TBK1 interaction.  No such residue was reported for IKKε.      
Extensive studies of coiled-coil domains have shown that in the formation of a 
coiled-coil dimer that hydrophobic residues, particularily leucine residues, are found on 
one face of the dimer and buried in the interior, which forms a hydrophobic core 
stabilizing the dimer interaction.  In fact, disruption of these leucine pairs even with other 
hydrophobic residues has lead to destabilization of the dimer.  This agrees with the 
predicted residues we found from the NAP1 KBD model we built that may stabilize dimer 
formation.  
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Quikchange mutagenesis kits (Stratagene) that employ standard molecular biology 
and polymerase chain reaction (PCR) techniques was performed, as per manufacturer’s 
protocol, to mutate a few of these residues: Y223A, Q240A, L244S (and L226/233/247S), 
E225A and E229A.  Mutagenesis has been completed for the following residues: Y223A, 
Q240A, L244S and E225A, highlighted in Figure 31A.  The remaining mutations are 
ongoing. 
Initial purification of the completed mutations has yielded poor results of pure and 
stable protein to use for future experiments (Figure 31B-C).  However, purification of the 
L244S mutant yielded enough sample (~3mg/ml) to analyze the oligomeric state (Figure 
32) by analysis over the S200 Tricorn column (in 20mM HEPES pH 7.5, 150mM NaCl, 
1mM βME).  The elution pattern indicates that it is eluting as mainly a monomeric species.  
However, this run would need to be repeated and additional concentrations tested to 
confirm.  This data suggests that the leucine residues are indeed required for dimer 
stabilization.  The rest of the leucines and other residues are currently being tested. 
The previously described mutants will be assessed for dimeric structure using SEC 
and NAP1-Kinase interactions via FRET to further elucidate the NAP1-TBK1/IKKε 
trimeric complex formation in this protein-interaction network and more importantly its 
specificity in downstream signaling. 
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Upon completion of mutagenesis, the mutated proteins will be assessed for dimeric 
structure using SEC and NAP1-Kinase interactions via FRET to further elucidate the 
NAP1-TBK1/IKKε role is this protein-interaction network and more importantly its role in 
mediating downstream signaling.
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